TPST: Tempest Therapeutics, Inc.
About
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.
Current Value
$0.901 Year Return
Current Value
$0.901 Year Return
Key Details
Market Cap
$37.75M
P/E Ratio
-0.56
1Y Stock Return
-77.59%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
2.0
Strategies that include TPST
Stock's related to TPST
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BLDP | 30.76% | $398.23M | -61.89% | 0.00% |
| ALHC | 28.91% | $2.13B | +65.77% | 0.00% |
| NATR | 27.76% | $295.06M | -7.42% | 0.00% |
| TY | 27.68% | - | - | 3.32% |
| USAP | 27.66% | $412.06M | +176.63% | 0.00% |
| GHM | 27.55% | $464.78M | +132.21% | 0.00% |
| SRG | 27.16% | $221.13M | -55.94% | 0.00% |
| BLNK | 26.91% | $156.82M | -57.53% | 0.00% |
| ARAY | 26.91% | $185.04M | -31.85% | 0.00% |
| ATNM | 26.73% | $44.30M | -67.05% | 0.00% |
| PDSB | 26.61% | $78.37M | -66.59% | 0.00% |
| VYGR | 26.21% | $287.88M | -21.46% | 0.00% |
| SPCE | 25.91% | $196.64M | -84.01% | 0.00% |
| CRESY | 25.83% | $681.63M | +31.28% | 6.73% |
| VIRC | 25.82% | $253.30M | +129.35% | 0.53% |
| PAYS | 25.75% | $176.71M | +37.50% | 0.00% |
| CPRI | 25.48% | $2.36B | -58.95% | 0.00% |
| RWAY | 25.31% | $394.72M | -17.18% | 15.47% |
| GBIO | 25.29% | $92.84M | +20.87% | 0.00% |
| RLMD | 25.08% | $89.92M | +1.36% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CNSL | <0.01% | $548.51M | +9.98% | 0.00% |
| CNQ | <0.01% | $71.04B | +1.89% | 6.81% |
| CARG | -0.01% | $3.68B | +69.13% | 0.00% |
| CIG | 0.01% | $3.88B | +7.91% | 0.00% |
| PENN | -0.01% | $3.10B | -19.87% | 0.00% |
| KT | 0.01% | $7.55B | +19.08% | 6.85% |
| HZO | -0.01% | $668.35M | -1.96% | 0.00% |
| ILPT | 0.01% | $253.33M | +31.62% | 1.05% |
| GNTX | -0.01% | $6.61B | -5.31% | 1.66% |
| HROW | 0.01% | $1.41B | +330.59% | 0.00% |
| CDNA | 0.01% | $1.18B | +132.21% | 0.00% |
| LGF.A | 0.02% | $1.83B | -20.52% | 0.00% |
| CABO | 0.02% | $2.24B | -27.54% | 2.99% |
| ALEC | -0.02% | $377.04M | -19.46% | 0.00% |
| VRRM | -0.02% | $3.79B | +17.16% | 0.00% |
| ITRN | 0.02% | $569.91M | +10.76% | 5.16% |
| ALTG | 0.03% | $236.78M | -29.08% | 3.22% |
| CADE | 0.03% | $6.82B | +53.20% | 2.64% |
| PUBM | 0.03% | $739.82M | -2.82% | 0.00% |
| ASO | -0.03% | $3.24B | -4.48% | 0.93% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DVA | -50.40% | $12.87B | +60.92% | 0.00% |
| FMS | -47.88% | $12.97B | +12.47% | 2.97% |
| BAX | -41.70% | $16.60B | -8.91% | 3.57% |
| LMAT | -32.86% | $2.33B | +94.89% | 0.46% |
| VSTO | -30.34% | $2.58B | +71.61% | 0.00% |
| BSX | -29.85% | $133.13B | +63.29% | 0.00% |
| BIRK | -28.02% | $8.75B | +7.40% | 0.00% |
| ZBH | -27.60% | $22.09B | -1.73% | 0.87% |
| SYK | -26.49% | $148.17B | +32.36% | 0.82% |
| LXFR | -25.02% | $387.04M | +72.02% | 3.60% |
| MDT | -23.46% | $109.01B | +8.12% | 3.27% |
| NARI | -21.96% | $2.98B | -11.66% | 0.00% |
| PODD | -20.39% | $18.38B | +44.49% | 0.00% |
| HUSA | -20.35% | $16.69M | -11.56% | 0.00% |
| BCO | -19.99% | $4.00B | +19.00% | 1.04% |
| ISRG | -19.96% | $191.92B | +72.80% | 0.00% |
| THC | -19.45% | $14.58B | +131.72% | 0.00% |
| KDP | -19.18% | $42.76B | -1.22% | 2.77% |
| XOM | -18.23% | $521.39B | +13.56% | 3.22% |
| QTRX | -17.93% | $424.47M | -53.12% | 0.00% |
ETF's related to TPST
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IHI | -28.74% | $4.91B | 0.4% |
| VIXY | -26.21% | $195.31M | 0.85% |
| GBIL | -25.89% | $5.60B | 0.12% |
| XHE | -24.48% | $213.41M | 0.35% |
| TBLL | -24.30% | $1.92B | 0.08% |
| BTAL | -21.63% | $388.04M | 1.43% |
| TAIL | -21.58% | $67.98M | 0.59% |
| BUXX | -20.87% | $162.67M | 0.25% |
| UCON | -18.75% | $3.19B | 0.85% |
| HTAB | -16.98% | $437.10M | 0.4% |
| IVOL | -15.98% | $548.70M | 1.02% |
| DFNM | -15.59% | $1.40B | 0.17% |
| XBIL | -14.77% | $637.70M | 0.15% |
| FMB | -14.76% | $2.03B | 0.65% |
| PWZ | -14.73% | $697.36M | 0.28% |
| SHYD | -13.99% | $311.50M | 0.35% |
| FLMI | -13.76% | $356.19M | 0.3% |
| HYD | -13.57% | $3.18B | 0.32% |
| TLTW | -13.15% | $1.09B | 0.35% |
| XHLF | -13.11% | $874.27M | 0.03% |
News
Yahoo
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trialReceived final funding approval from NCI to move TPST-1495 into a Phase 2 trial in FAPExpanded leadership team to strengthen global clinical expertise BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Temp
Yahoo
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in a pivotal
Yahoo
The company is preparing for the Phase 3 study start in the first quarter of 2025BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced an agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for unresectable
Yahoo
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or the “Company”), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that its Board of Directors (the “Board”) has adopted an amendment to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan until the Annual Meeting of Stockhold
Yahoo
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 79,500 shares of its common stock under the Company’s 2023 Inducement Plan. The stock options will vest over a four-ye
Yahoo
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.